InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (96 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
96
T+90 hit rate
0%
T+90 mean return
-7.6%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by EDGEMOND JAMES, Chief Financial Officer. Director active across 1 company, notably UNITED THERAPEUTICS Corp. Aggregated, 120 disclosures have been recorded. Split: 0 buy · 96 sells. Total volume traded: €24.3m. History available since 7 November 2022. The latest transaction was filed on 4 June 2026 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations120 total
8,750 sharesCommon StockSEC:0001636178-26-000029:0
164 sharesCommon StockSEC:0001636178-26-000029:1
865 sharesCommon StockSEC:0001636178-26-000029:2
1,091 sharesCommon StockSEC:0001636178-26-000029:3
840 sharesCommon StockSEC:0001636178-26-000029:4
2,266 sharesCommon StockSEC:0001636178-26-000029:5
1,994 sharesCommon StockSEC:0001636178-26-000029:6
280 sharesCommon StockSEC:0001636178-26-000029:7
1,250 sharesCommon StockSEC:0001636178-26-000029:8
10,000 sharesCommon StockSEC:0001636178-26-000028:0
400 sharesCommon StockSEC:0001636178-26-000028:1
160 sharesCommon StockSEC:0001636178-26-000028:2
210 sharesCommon StockSEC:0001636178-26-000028:3
600 sharesCommon StockSEC:0001636178-26-000028:4
1,440 sharesCommon StockSEC:0001636178-26-000028:5
2,035 sharesCommon StockSEC:0001636178-26-000028:6
2,978 sharesCommon StockSEC:0001636178-26-000028:7
865 sharesCommon StockSEC:0001636178-26-000028:8
192 sharesCommon StockSEC:0001636178-26-000028:9
40 sharesCommon StockSEC:0001636178-26-000028:10
40 sharesCommon StockSEC:0001636178-26-000028:11
265 sharesCommon StockSEC:0001636178-26-000028:12
115 sharesCommon StockSEC:0001636178-26-000028:13
660 sharesCommon StockSEC:0001636178-26-000028:14
121 sharesCommon StockSEC:0001636178-26-000027:1
25 of 120 declarations
About EDGEMOND JAMES
James Edgemond is the Chief Financial Officer and Treasurer of United Therapeutics Corp. In this role, he is responsible for the company's financial management, including financial planning and risk management. James brings expertise in finance and accounting, contributing to United Therapeutics' performance and growth. His commitment to financial transparency is essential for maintaining investor trust.
